Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 20

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 20
---
 equal to the fractional
amount multiplied by the exercise price.

Insider Participation

In the April 2024 Offering, certain of our officers
and directors agreed to purchase the April 2024 Warrants on the same terms as described herein, except that (i) the combined offering
price per share of common stock and accompanying April 2024 Warrant for officers and directors sold in the April 2024 Offering was $8.445
and (ii) in the event that the April 2024 Warrants are held by our directors, officers or other affiliates and the termination date is
during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in our common stock, such
officers or affiliates will have an additional 60 days from the termination of the blackout date to exercise the April 2024 Warrants.

<div align='center'>S-9</div>

Second April 2024 Warrants

Duration and Exercise Price

Each Second April 2024 Warrant
has an initial exercise price of $9.84 per share. The Second April 2024 Warrants became exercisable on April 29, 2024, and will expire
on the later of (i) April 29, 2026 or (ii) thirty (30) trading days following the public announcement by us reporting positive top line
data (EMACC with a p-value less than or equal to 0.05) of our Phase 2 Alzheimer’s program of XPRO1595. The exercise price and number
of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations
or similar events affecting our common stock and the exercise price. Each Second April 2024 Warrant is exercisable for one share of common
stock.

Exercisability

The Second April 2024 Warrants
is exercisable, at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment
in full for the number of purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together
with its affiliates) may not exercise any portion of the Second April 2024 Warrant to the extent that the holder would own more than 4.99%
(or, at the election of a purchaser, 9.99%) of the outstanding common stock immediately after exercise, except that upon at least 61 days